Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (57)

I-01Jeroen Elassaiss-Schaap

Translational Pharmacokinetic/Pharmacodynamic Model of Tumor Growth Inhibition by the New Anti-PD1 Monoclonal Antibody MK-3475

Wednesday 10:20-11:50

I-02Moran Elishmereni

Improved sunitinib therapy in non-small cell lung cancer as predicted by a new mixed-effects model

Wednesday 10:20-11:50

I-03Yumi Yamamoto

Toward a generic PBPK model to predict drug distribution in human brain

Wednesday 10:20-11:50

I-04Farkad Ezzet

Dose Response Models for Multiple Endpoints: A Simulation Study

Wednesday 10:20-11:50

I-05

Impact of maternal zidovudine infusions at labor on fetus: a population pharmacokinetic study

Wednesday 10:20-11:50

I-06Sylvain Fouliard

Cardiac safety monitoring in early oncology trials using optimal design and M&S approach

Wednesday 10:20-11:50

I-07Tomoko Freshwater

Competitive landscape model using meta-analysis and simulation-based evaluation for Phase IIb study design of MRL-1 being developed for the treatment of rheumatoid arthritis

Wednesday 10:20-11:50

I-08Aline Fuchs

Impact of medication adherence measurement on antiretroviral drug pharmacokinetics: A retrospective cohort study in HIV patients followed by therapeutic drug monitoring and taking part in a medication-adherence enhancing program

Wednesday 10:20-11:50

I-09María José García Sánchez

PBPK analysis of doxorrubicin tissue uptake by Simcyp® simulator: influence of gender related variables

Wednesday 10:20-11:50

I-10María García-Cremades

Pharmacokinetic and Pharmacodynamic analysis of Gemcitabine in pancreatic cancer in mice.

Wednesday 10:20-11:50

I-11Marc Gastonguay

Proposal for a Web-Based Open Pharmacometrics Curriculum: Results of a Four-Month Pilot Evaluation

Wednesday 10:20-11:50

I-13Eva Germovsek

Mechanistic Modelling of Total Body CD4 T-cell Counts from Paediatric HIV Patients Undergoing Planned Treatment Interruption

Wednesday 10:20-11:50

I-14Ekaterina Gibiansky

Population Pharmacokinetics of Obinutuzumab (GA101) in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL)

Wednesday 10:20-11:50

I-15Leonid Gibiansky

Numerical Testing of Assumptions for Target-Mediated Drug Disposition (TMDD) Equations: Why Inexact Model Provides Satisfactory Description?

Wednesday 10:20-11:50

I-16Sandra Gil

Modeling the Postantifungal Effect of Anidulafungin Against Candida

Wednesday 10:20-11:50

I-17Anais Glatard

A model-based approach to support NOAEL determination: a simulation case illustrated by a real dataset

Wednesday 10:20-11:50

I-18Bojana Golubovic

Population pharmacokinetics of sirolimus in adult kidney transplant patients

Wednesday 10:20-11:50

I-19Marta Gonzalez

In-silico Biopharmaceutical Systems for Provisional Classification of Oral Drugs

Wednesday 10:20-11:50

I-20Ignacio Gonzalez-Garcia

Simulations of populations with different creatinine clearance range and weight to select the best dose of NV22413

Wednesday 10:20-11:50

I-21Mario Gonzalez Sales

Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy volunteers.

Wednesday 10:20-11:50

I-22Isabel Gonzalez-Alvarez

Semi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acid

Wednesday 10:20-11:50

I-23Sathej Gopalakrishnan

Assessing treatment failure under combination therapy in HIV disease

Wednesday 10:20-11:50

I-24Verena Gotta

Power of PKPD analysis to detect QTc effect in preclinical setting

Wednesday 10:20-11:50

I-25Abhishek Gulati

Modeling the effect of interferon beta-1b on contrast enhancing lesions in relapsing-remitting multiple sclerosis

Wednesday 10:20-11:50

I-26Serge Guzy

Evaluation of Bias and Precision using QRPEM algorithm in Phoenix NLME for discrete data models

Wednesday 10:20-11:50

I-27Chihiro Hasegawa

Modeling & simulation of ONO-5334, a cathepsin K inhibitor, to support dose selection in osteoporosis

Wednesday 10:20-11:50

I-28Michael Heathman

Concentration-Response Modeling of Adverse Event Data using a Markov Chain Approach

Wednesday 10:20-11:50

I-29Stefanie Hennig

Population pharmacokinetics of high dose methotrexate in non-Hodgkin lymphoma patients

Wednesday 10:20-11:50

I-30Christoph Hethey

Towards a cell-level model to predict bacterial growth under antimicrobial perturbation

Wednesday 10:20-11:50

I-31Jules Heuberger

The prior subroutine explored: pharmacokinetic modeling of THC

Wednesday 10:20-11:50

I-32

Virtual Tumour Clinical: translational modelling of vemurafenib, selumetinib and docetaxel inmetastatic melanoma

Wednesday 10:20-11:50

I-33Rollo Hoare

Modelling CD4 lymphocyte reconstitution following paediatric haematopoietic stem cell transplantation

Wednesday 10:20-11:50

I-34Nick Holford

Evaluation of NONMEM and Monolix by Parametric Bootstrap

Wednesday 10:20-11:50

I-35Xiao Hu

Exposure-Response Analysis of Peginterferon beta-1a in Subjects with Relapsing Remitting Multiple Sclerosis

Wednesday 10:20-11:50

I-36Kimberley Jackson

Population Pharmacokinetic (PK) Modelling of Ketamine and Norketamine in Plasma, Prefrontal Cortex (PFC) and Cerebrospinal Fluid (CSF) after Subcutaneous (SC) Administration of S(+)-Ketamine in Rats.

Wednesday 10:20-11:50

I-37

Model based optimization of a novel controlled release formulation of capecitabine

Wednesday 10:20-11:50

I-38Esther Janssen

Simulations of vancomycin exposure throughout childhood upon commonly used dosing guidelines: towards a model-based dosing regimen

Wednesday 10:20-11:50

I-39Petra Jauslin

Comparison of post-prandial glucose control by two GLP-1 receptor agonists (lixisenatide and liraglutide) in type 2 diabetes

Wednesday 10:20-11:50

I-40Garrit Jentsch

The BAST Clinical Trial Simulator: A computational framework for quantitative risk assessment.

Wednesday 10:20-11:50

I-41Jin Jin

Longitudinal Safety Modeling and Simulation for Regimen Optimization of Vismodegib in Operable Basal Cell Carcinoma

Wednesday 10:20-11:50

I-42Niclas Jonsson

A Population PK Analysis of Nebivolol and Valsartan in Combination Therapy

Wednesday 10:20-11:50

I-43Marija Jovanovic

Effect of Valproic Acid Daily Dose on Phenobarbital Clearance – Nonlinear Mixed Effects Modelling Approach

Wednesday 10:20-11:50

I-44Rasmus Juul Kildemoes

How Repeated Time To Event (RTTE) modelling of opioid requests after surgery may improve future post-operative pain management

Wednesday 10:20-11:50

I-45Ana Novakovic

Sample size calculations in multiple sclerosis using pharmacometrics methodology: comparison of a composite score continuous modeling and Item Response Theory approach

Wednesday 10:20-11:50

I-46Kristin Karlsson

Estimating a Cox proportional hazard model in NONMEM

Wednesday 10:20-11:50

I-47Mats Karlsson

Item response theory for analyzing placebo and drug treatment in Phase 3 studies of schizophrenia

Wednesday 10:20-11:50

I-48Takayuki Katsube

Population PK/PD Modeling of Lusutrombopag, Thrombopoietin Receptor Agonist, in Healthy Volunteers for Exploring PK/PD Covariates

Wednesday 10:20-11:50

I-49Irene-Ariadne Kechagia

A meta-analysis methodology to estimate population pharmacokinetic parameters from reported non-compartmental values with sparse sampling

Wednesday 10:20-11:50

I-50Ron Keizer

Expected effectiveness of reduced-dose efavirenz

Wednesday 10:20-11:50

I-51David Khan

Evaluation of Mechanism Based PKPD Model for Antibiotics

Wednesday 10:20-11:50

I-52

Metformin’s glucose lowering effect in healthy volunteers receiving an oral glucose tolerance test

Wednesday 10:20-11:50

I-53Yo Han Kim

Early characterization of ticagrelor using modeling and simulation analysis of the in vitro platelet aggregation test and human pharmacokinetic data

Wednesday 10:20-11:50

I-55William Knebel

Elastic Cloud Computing in Pharmacometrics: Usage Data and Strategies for Efficient Workflows

Wednesday 10:20-11:50

I-56Gilbert Koch

Solving Semi-Delay Differential Equations in NONMEM

Wednesday 10:20-11:50

I-57Markus Krauß

Hierarchical Bayesian-PBPK modeling for physiological characterization and extrapolation of patient populations from clinical data

Wednesday 10:20-11:50

I-58Mads Kreilgaard

Study design optimization of a morphine analgesia trial using PKPD modelling and simulation

Wednesday 10:20-11:50

I-59Ryuji Kubota

Population Pharmacokinetics of Ospemifene and Evaluation for Exposure Increase

Wednesday 10:20-11:50